Catalyst

Slingshot members are tracking this event:

Egalet (EGLT) Plans U.S Commercial Launch of ARYMO ER C-II for Treatment of Chronic Pain in Q1 2017

Source Link:
http://egalet.investorroom.com/2017-01-09-Egalet-Receives-FDA-Approval-for-ARYMO-ER-morphine-sulfate-C-II-an-Extended-Release-Morphine-Product-Formulated-with-Abuse-Deterrent-Properties-for-Treatment-of-Chronic-Pain

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
EGLT
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 30, 2017
Occurred Source:
http://egalet.investorroom.com/2017-03-30-Egalet-Deploys-Salesforce-to-Begin-Educating-Healthcare-Providers-about-ARYMO-TM-ER
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords U.s Commercial Launch, Arymo Er C-ii, Chronic Pain
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.